Showing 141 - 160 results of 4,532 for search '(sars OR (cheers OR (when OR (sheep OR (steer OR steep)))))*', query time: 0.18s Refine Results
  1. 141

    A 9.87 nW 1 kS/s 8.7 ENOB SAR ADC for implantable epileptic seizure detection microsystems by Do, Anh Tuan, Lam, Chun Kit, Tan, Yung Sern, Yeo, Kiat Seng, Cheong, Jia Hao, Yao, Lei, Tan, Meng Tong, Je, Minkyu

    Published 2013
    “…This paper presents an ultra low-power SAR ADC in 0.18 μm CMOS technology for epileptic seizure detection applications. …”
    Get full text
    Get full text
    Conference Paper
  2. 142
  3. 143
  4. 144
  5. 145

    Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool by Puarattana-aroonkorn, Sitthiphol, Tharakaraman, Kannan, Suriyawipada, Disapan, Ruchirawat, Mathuros, Fuangthong, Mayuree, Sasisekharan, Ram, Artpradit, Charlermchai

    Published 2024
    “…We demonstrated that the production of SARS-CoV-2 VLPs using this cell pool was scalable up to a stirred-tank 2 L bioreactor in fed-batch mode. …”
    Get full text
    Article
  6. 146

    Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain by Yang, Leerang, Van Beek, Matthew, Wang, Zijun, Muecksch, Frauke, Canis, Marie, Hatziioannou, Theodora, Bieniasz, Paul D, Nussenzweig, Michel C, Chakraborty, Arup K

    Published 2024
    “…The Omicron variant of SARS-CoV-2 is not effectively neutralized by most antibodies elicited by two doses of mRNA vaccines, but a third dose increases anti-Omicron neutralizing antibodies. …”
    Get full text
    Article
  7. 147

    Determining optimal timing of birth for women with chronic or gestational hypertension at term: the WILL (When to Induce Labour to Limit risk in pregnancy hypertension) randomised trial by Magee, LA, Kirkham, K, Tohill, S, Gkini, E, Moakes, CA, Dorling, J, Green, M, Hutcheon, JA, Javed, M, Kigozi, J, Mol, BWM, Singer, J, Hardy, P, Stubbs, C, Thornton, JG, von Dadelszen, P, WILL Trial Study Group

    Published 2024
    “…A total of 403 participants (37.3% of target) were randomised to the intervention (n = 201) or control group (n = 202), from 3 June 2019 to 19 December 2022, when the funder stopped the trial for delayed recruitment. …”
    Journal article
  8. 148

    Dynamics of SARS-CoV-2 infection over two epidemic waves in Manaus, Brazil: A serological study of seven thousand blood donors by Alexander, N, Dye, C, Busch, MP, Buss, L, Prete, CA, Brady, OJ, Mee, P, Abrahim, CMM, Crispim, MAE, da Costa, AG, Salomon, T, Mayaud, P, Oikawa, MK, Faria, NR, Sabino, EC

    Published 2025
    “…Seroconversion was inferred by a mixture model for serial values from the Abbott Architect SARS-CoV-2 nucleocapsid (N) IgG assay. We estimated the number of suspected COVID-19 hospitalizations arising from each infection over calendar time. …”
    Journal article
  9. 149
  10. 150
  11. 151
  12. 152

    The cellular characterization of SARS-CoV-2 spike protein in virus-infected cells using the receptor binding domain binding specific human monoclonal antibodies by Chan, Conrad En-Zuo, Ng, Ching-Ging, Lim, Angeline Pei-Chew, Seah, Shirley Lay-Kheng, Chye, De-Hoe, Wong, Steven Ka-Khuen, Lim, Jie-Hui, Lim, Vanessa Zi-Yun, Lai, Soak-Kuan, Wong, Pui-San, Leong, Kok-Mun, Liu, Yi-Chun, Sugrue, Richard J., Tan, Boon Huan

    Published 2022
    “…A human monoclonal antibody panel (PD4, PD5, PD7, SC23, and SC29) was isolated from the B cells of convalescent patients and used to examine the S protein in SARS-CoV-2-infected cells. While all five antibodies bound conformational-specific epitopes within SARS-CoV-2 spike (S) protein, only PD5, PD7, and SC23 were able to bind to the receptor binding domain (RBD). …”
    Get full text
    Journal Article
  13. 153
  14. 154
  15. 155

    Socioeconomic inequalities in risk of infection with SARS-CoV-2 delta and omicron variants in the UK, 2020-22: analysis of the longitudinal COVID-19 Infection Survey by Razieh, C, Shabnam, S, Dambha-Miller, H, Morris, EJA, Yates, T, Chudasama, Y, Zaccardi, F, Gillies, C, Banerjee, A, Pareek, M, Lacey, B, White, M, Khunti, K, Islam, N

    Published 2024
    “…<p><strong>Objective</strong> To explore the risk of a positive test result for the delta or omicron variant of the SARS-CoV-2 virus in different occupations and deprivation groups in the UK.…”
    Journal article
  16. 156

    Effectiveness and user experience of nose and throat swabbing techniques for SARS-CoV-2 detection: results from the UK COVID-19 National Testing Programme by Futschik, ME, Kulasegaran-Shylini, R, Blandford, E, Harper, S, Chapman, D, Turek, E, Agrawal, S, Phillips, V, Fordham, H, Chan, L, Kidd, M, Dodgson, A, Klapper, PE, Sudhanva, M, Vipond, R, Hopkins, S, Peto, T, Tunkel, S, Fowler, T

    Published 2025
    “…Background: The UK’s National Health Service Test and Trace (NHSTT) program aimed to provide the most effective and accessible SARS-CoV-2 testing approach possible. Early user feedback indicated that there were accessibility issues associated with throat swabbing. …”
    Journal article
  17. 157
  18. 158

    Virus-like particles of nodavirus displaying the receptor binding domain of SARS-CoV-2 spike protein: a potential VLP-based COVID-19 vaccine by Kumar, Kiven, Tan, Wen Siang, Arshad, Siti Suri, Ho, Kok Lian

    Published 2023
    “…The efficacy of the initial vaccines based on the ancestral strain of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has become a point of contention due to the emergence of new variants of concern (VOCs). …”
    Get full text
    Article
  19. 159
  20. 160